Warner-1998

MethodsPhase II study, non comparative
Participants and Country33 patients with CUP not belonging to a treatable sub-group. PS 2 or less. 30/33 adenocarcinoma, 3/33 undifferentiated carcinoma
InterventionsCombined carboplatin and etoposide
OutcomesTreatment response
Prognostic factors (univariate)Age, sex, performance status, histology, site of disease
Prognostic factors (multivariate)Not reported
Notes

From: Guideline chapter 3, Factors Influencing Management

Cover of Diagnosis and Management of Metastatic Malignant Disease of Unknown Primary Origin
Diagnosis and Management of Metastatic Malignant Disease of Unknown Primary Origin.
NICE Clinical Guidelines, No. 104.
National Collaborating Centre for Cancer (UK).
Copyright © 2010, National Collaborating Centre for Cancer.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licenses issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.